Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study is a research paper published in American Journal of Hematology (2024). On theSindex it has a DataRank of 0.330. It has been cited 8 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →belantamab mafodotin for this study
Grant: NCT04808037
GlaxoSmithKline
GlaxoSmithKline
FWCI
2.46
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals